Fresenius Kabi announces FDA approval of lipid injectable emulsion for parenteral nutrition

image credit- businesswire

First and only four-oil lipid injectable emulsion indicated for peadiatric parenteral nutrition, including term and preterm neonates

Fresenius Kabi has been granted an expanded indication for SMOFlipid® Lipid Injectable Emulsion (ILE) for peadiatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age. SMOFlipid can be used throughout the continuum of care from the hospital to home care settings.

Parenteral nutrition is the intravenous administration of amino acids (protein), carbohydrates (dextrose), lipids (fats), electrolytes, vitamins, and other trace elements for patients who cannot digest or absorb sufficient nutrition via the gastrointestinal tract.

SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Read Previous

Diageo invests £40.5 M in beer packaging facilities

Read Next

FarMart secures funds worth $32 M to scale up food supply platform

Leave a Reply

Most Popular